[go: up one dir, main page]

WO2008133036A1 - 腎尿細管障害治療剤のスクリーニング方法 - Google Patents

腎尿細管障害治療剤のスクリーニング方法 Download PDF

Info

Publication number
WO2008133036A1
WO2008133036A1 PCT/JP2008/057148 JP2008057148W WO2008133036A1 WO 2008133036 A1 WO2008133036 A1 WO 2008133036A1 JP 2008057148 W JP2008057148 W JP 2008057148W WO 2008133036 A1 WO2008133036 A1 WO 2008133036A1
Authority
WO
WIPO (PCT)
Prior art keywords
screening
renal tubular
compound
therapeutic agent
macrophage
Prior art date
Application number
PCT/JP2008/057148
Other languages
English (en)
French (fr)
Inventor
Michio Ishibashi
Original Assignee
Michio Ishibashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michio Ishibashi filed Critical Michio Ishibashi
Priority to JP2009511777A priority Critical patent/JPWO2008133036A1/ja
Publication of WO2008133036A1 publication Critical patent/WO2008133036A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　腎臓の尿細管病変の予防、緩和または治療できる化合物のスクリーニング方法を提供すること。ヒト末梢血単核球またはヒト単球もしくはヒトマクロファージの性質を有するヒト培養細胞樹立株とマクロファージ活性化物質とが接触して惹起されるｒＢＡＴの発現に対して被検化合物が示す調節作用を検定することを特徴とする腎臓の尿細管病変を予防、緩和または治療する化合物のスクリーニング方法。
PCT/JP2008/057148 2007-04-12 2008-04-11 腎尿細管障害治療剤のスクリーニング方法 WO2008133036A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009511777A JPWO2008133036A1 (ja) 2007-04-12 2008-04-11 腎尿細管障害治療剤のスクリーニング方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-105067 2007-04-12
JP2007105067 2007-04-12
JP2007187486 2007-07-18
JP2007-187486 2007-07-18

Publications (1)

Publication Number Publication Date
WO2008133036A1 true WO2008133036A1 (ja) 2008-11-06

Family

ID=39925495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057148 WO2008133036A1 (ja) 2007-04-12 2008-04-11 腎尿細管障害治療剤のスクリーニング方法

Country Status (2)

Country Link
JP (1) JPWO2008133036A1 (ja)
WO (1) WO2008133036A1 (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072730A1 (fr) * 2000-03-28 2001-10-04 Michio Ishibashi Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072730A1 (fr) * 2000-03-28 2001-10-04 Michio Ishibashi Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORA ET AL.: "The rBAT Gene Is Responsible for L-Cystine Uptake via the b0, +-like Amino Acid Transport System in a "Renal Proximal Tubular" Cell Line (OK Cells)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 1996, pages 10569 - 10576 *

Also Published As

Publication number Publication date
JPWO2008133036A1 (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2010091049A3 (en) Diagnosis and treatment of cancer
UA98629C2 (ru) Соединения и способ модуляции киназ
WO2006119467A3 (en) Protein activity modification
WO2010118035A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2007027788A3 (en) Analyte sensor introducer and methods of use
WO2007005180A3 (en) Method for enhancing engraftment of therapeutic cells at a target site
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
EP2367007A3 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
WO2007136790A3 (en) Intracellular kinase inhibitors
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2006032134A3 (en) Radiotherapy treatment monitoring using ultrasound
EP2402752A3 (en) A method for pharmacologically profiling compounds
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2007038501A3 (en) Rheumatoid arthritis markers
EP1883446B8 (en) An implantable therapy system for treating a living being with an active factor
EP2079518A4 (en) METHOD, DEVICE, IMPLANTABLE STIMULATOR AND DOUBLE CHAMBER HEART THERAPY SYSTEM
NO20081045L (no) Forbindelser og fremgangsmater for behandling av cancer
WO2008147483A8 (en) Neurogenic compounds
EP1929946A4 (en) DEVICE FOR DETECTING THE BREAK OF THE HEART, THE BREATHING AND THE BEHAVIOR OF SMALL ANIMALS
PT3295954T (pt) Agente para utilização no caso de intolerância intestinal à frutos
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
EA201101300A1 (ru) Способ или система на основе биомаркеров, предназначенная для мониторинга лечения
WO2007117589A3 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
WO2011050328A3 (en) Assessment of solid tumor burden
EP1885851A4 (en) METHODS OF DIAGNOSING THE TRANGENERAL EFFECTS OF ENVIRONMENTAL TOXIC SUBSTANCES ON MAMMALIAN GERMINAL CELLS AND TREATING ASSOCIATED DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740245

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511777

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740245

Country of ref document: EP

Kind code of ref document: A1